Table 3.
HR and 95% CI of the association of metformin use, and overall mortality in diabetic pancreatic cancer patients.
| Variable | Multivariate-Adjusted HR * (95% CI) | p-Value |
|---|---|---|
| By metformin use | ||
| Non-users | 1.00 | ref. |
| Users | 0.85 (0.70–1.04) | 0.12 |
| By metformin cumulative dose | ||
| Non-users | 1.00 | ref. |
| <920.000 | 0.94 (0.72–1.21) | 0.62 |
| 920.000–1.840.000 | 0.87 (0.67–1.12) | 0.28 |
| >1.840.000 | 0.76 (0.58–0.99) | 0.04 |
| By antihyperglycemic medication ** | ||
| Sulfonylurea | 1.00 | ref. |
| Metformin | 0.74 (0.54–1.02) | 0.07 |
* adjusted for gender, age group, stage of pancreatic cancer, and histology; ** monotherapy groups only.